Affymetrix, Inc.

Alexza Pharmaceuticals, Inc.

Baxter Diagnostics Inc.

Affymax Technologies, N.v.

Calera Corporation

Other

Alexza Molecular Delivery Corporation

Prosetta Antiviral, Inc.

Baxter International Inc.

Alza Corporation

Baxter Travenol Laboratories, Inc.

Prosetta Biosciences, Inc.

Affymetrix Lnc.

Dennis Solas

Ron L Hale

William J Dower

Stephen P A Fodor

Joshua D Rabinowitz

Alejandro C Zaffaroni

Stephen P Fodor

Curtis Peter Tom

Soonho Song

Christopher P Holmes

Daniel J Myers

Reynaldo J Quintana

Ryan J Gilliam

Lubert Stryer

Margarete K Leclerc

James L Winkler

Pravin L Soni

Michael Joseph Weiss

Kyle Self

Thomas A Albrecht

Krishnamohan Sharma

Amy Tsai Lu

Mingzu Lei

Anatoliy Kitaygorodskyy

Ramesh Damani

Alexander A Gorer

Peter Lloyd

Michael Kostowskyj

Andy Atuegbu

Bryan Boggs

Clarence R Hurt

Hilary N Pettit

Martin J Wensley

Michel J Cormier

Vishwanath R Lingappa

Harold E Selick

Xiaohua C Huang

Kevin R Oldenburg

Kumarapandian Paulvannan

Stephen Pa Fodor

Patrik Munzar

Matthew D Stracker

Hale L Ron

Kirshnamohan Sharma

Described herein are compounds, pharmaceutical compositions and methods of using these compounds and pharmaceutical compositions for treating and/or preventing conditions such as amyotrophic lateral sclerosis. These compounds and pharmaceutical compositions are also useful as antivirals and antimicrobial agents.

Isoquinoline derivatives, methods of synthesis and uses thereof

This invention provides, among other things, tetrahydroisoquinolines useful for treating viral infections, pharmaceutical formulations containing such compounds, as well as methods of inhibiting the replication of a virus, such as HIV, or treating a disease, such as AIDS.

2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds

There are provided electrochemical methods and systems to form one or more organic compounds or enantiomers thereof selected from the group consisting of substituted or unsubstituted dioxane, substituted or unsubstituted dioxolane, dichloroethylether, dichloromethyl methyl ether, dichloroethyl methyl ether, chloroform, carbon tetrachloride, phosgene, and combinations thereof.

Electrochemical systems and methods using metal halide to form products

Anti-HIV compounds

Heating units, drug supply units and drug delivery articles capable of rapid heating are disclosed. Heating units comprising a substrate and a solid fuel capable of undergoing an exothermic metal oxidation reaction disposed within the substrate are disclosed. These heating units can be actuated by electrical resistance, by optical ignition or by percussion. Drug supply units and drug delivery articles wherein a solid fuel is configured to heat a substrate to a temperature sufficient to rapidly thermally vaporize a drug disposed thereon are also disclosed.

Self-contained heating unit and drug-supply unit employing same

There are provided methods and systems for an electrochemical cell including an anode and a cathode where the anode is contacted with a metal ion that converts the metal ion from a lower oxidation state to a higher oxidation state. The metal ion in the higher oxidation state is reacted with hydrogen gas, an unsaturated hydrocarbon, and/or a saturated hydrocarbon to form products.

Electrochemical hydroxide systems and methods using metal oxidation

Electrochemical systems and methods using metal and ligand

High sparking initiator compositions with a controlled amount of power are disclosed. The initiator compositions comprise a metal containing oxidizing agent, at least one metal reducing agent, and a non-explosive binder. Low voltage igniters that provide bidirectional plumes upon ignition are also disclosed. These igniters have a electrically resistive element positioned across a hole in a support which directs the plume. These igniters and compositions are useful in the actuation of solid fuel heating unit, in particular, sealed heating units.

Stable initiator compositions and igniters

A device, method, and system for producing a condensation aerosol are disclosed. The device includes a chamber having an upstream opening and a downstream opening which allow gas to flow through the chamber, and a heat-conductive substrate located at a position between the upstream and downstream openings. Formed on the substrate is a drug composition film containing a therapeutically effective dose of a drug when the drug is administered in aerosol form. A heat source in the device is operable to supply heat to the substrate to produce a substrate temperature greater than 300&#xb0; C., and to substantially volatilize the drug composition film from the substrate in a period of 2 seconds or less. The device produces an aerosol containing less than about 10% by weight drug composition degradation products and at least 50% of the drug composition of said film.

Rapid-heating drug delivery article and method of use

Aerosol drug delivery devices incorporating percussively activated heat packages are disclosed. The heat packages include a percussive igniter and a fuel capable of undergoing an exothermic oxidation-reduction reaction when ignited by the percussive igniter. The drug delivery devices disclosed can be activated by an actuation mechanism to vaporize a thin solid film comprising a drug disposed on the exterior of a hat package. Metal coordination complexes of volatile drugs, and in particular nicotine, from which the drug can be selectively vaporized when heated are also disclosed. The use of aerosol drug delivery devices comprising thin films of nicotine metal salt complexes for the treatment of nicotine craving and for effecting smoking cessation are also disclosed.

Aerosol drug delivery device incorporating percussively activated heat packages

The present invention relates to the delivery of migraine headache drugs through an inhalation route. Specifically, it relates to aerosols containing migraine headache drugs that are used in inhalation therapy.

Delivery of compounds for the treatment of headache through an inhalation route

The present invention relates to the delivery of compounds for the treatment of migraine and headache through an inhalation route. Specifically, it relates to aerosols containing rizatriptan or zolmitriptan that are used in inhalation therapy. In a method aspect of the present invention, rizatriptan or zolmitriptan is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of rizatriptan or zolmitriptan on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering rizatriptan or zolmitriptan through an inhalation route is provided which comprises: a) a thin coating of a rizatriptan or zolmitriptan composition; and, b) a device for dispending said thin coating as a condensation aerosol.

Delivery of rizatriptan or zolmitriptan through an inhalation route

Growing community of inventors

San Francisco, CA, United States of America

Dennis Solas